Objectives Direct oral anticoagulants (DOACs) were introduced based on randomised
controlled trials (RCTs) comparing them to vitamin-K-antagonist (VKA) warfarin. In Germany …

Objective One legitimate aim of the pharmaceutical industry is maximizing profit. In an
ageing population this can for example be achieved with preventive therapies for older …

Background For stroke prevention in patients with atrial fibrillation (AF), direct oral
anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists …

All pivotal trials have evaluated non–vitamin K oral antagonists (NOACs) against warfarin.
However, in some regions of the world, phenprocoumon is the most widely used vitamin K …

Abstract Background Direct oral anticoagulants (DOACs) are not only increasingly being
used for the initial stroke prevention therapy but progressively also substitute vitamin K …

Objective To compare the real-world effectiveness and safety of non-vitamin-K-antagonist
oral anticoagulant (NOAC) treatment in atrial fibrillation (AF) patients with a vitamin-K …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective
and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All …

Background: Non-vitamin K oral anticoagulants (NOACs) are an alternative to warfarin in the
prevention of stroke in non-valvular atrial fibrillation (NVAF). Nordic countries have high …

Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …

Background The benefit of direct oral anticoagulants (DOACs) versus vitamin K antagonists
(VKAs) on major bleeding was less prominent among atrial fibrillation (AF) patients with …